Trending Stock News

Bonterra Energy (BNE) Analysts See $0.13 EPS; Amag Pharmaceuticals (AMAG) Sentiment Is 0.9

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Logo

Amag Pharmaceuticals Inc (AMAG) investors sentiment decreased to 0.9 in 2017 Q4. It’s down -0.54, from 1.44 in 2017Q3. The ratio turned negative, as 74 active investment managers started new and increased stock positions, while 82 sold and trimmed positions in Amag Pharmaceuticals Inc. The active investment managers in our database now own: 37.72 million shares, down from 39.98 million shares in 2017Q3. Also, the number of active investment managers holding Amag Pharmaceuticals Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 29 Reduced: 53 Increased: 50 New Position: 24.

Analysts expect Bonterra Energy Corp (TSE:BNE) to report $0.13 EPS on May, 9.They anticipate $0.12 EPS change or 1,200.00% from last quarter’s $0.01 EPS. T_BNE’s profit would be $4.33 million giving it 31.13 P/E if the $0.13 EPS is correct. After having $0.06 EPS previously, Bonterra Energy Corp’s analysts see 116.67% EPS growth. The stock increased 1.00% or $0.16 during the last trading session, reaching $16.19. About 162,617 shares traded or 21.18% up from the average. Bonterra Energy Corp (TSE:BNE) has 0.00% since May 8, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock increased 2.99% or $0.6 during the last trading session, reaching $20.7. About 1.16M shares traded. AMAG Pharmaceuticals, Inc. (AMAG) has declined 16.25% since May 8, 2017 and is downtrending. It has underperformed by 27.80% the S&P500.

Ratings analysis reveals 33% of AMAG Pharma’s analysts are positive. Out of 3 Wall Street analysts rating AMAG Pharma, 1 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. AMAG was included in 3 notes of analysts from October 27, 2016. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Buy” rating given on Thursday, October 27 by Needham. The stock has “Mkt Perform” rating by Leerink Swann on Tuesday, January 10. The firm has “Underperform” rating by Raymond James given on Monday, January 9.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $16,016 activity.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $710.56 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

Palo Alto Investors Llc holds 1.99% of its portfolio in AMAG Pharmaceuticals, Inc. for 3.49 million shares. Camber Capital Management Llc owns 2.65 million shares or 1.72% of their US portfolio. Moreover, Falcon Point Capital Llc has 1.53% invested in the company for 685,237 shares. The New York-based Eii Capital Management Inc. has invested 0.67% in the stock. Kamunting Street Capital Management L.P., a Connecticut-based fund reported 67,460 shares.

More notable recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: Nasdaq.com which released: “AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer” on May 02, 2018, also Nasdaq.com with their article: “AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance” published on May 03, 2018, Nasdaq.com published: “AMAG Pharmaceuticals to Present at Upcoming Investor Conferences” on April 27, 2018. More interesting news about AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were released by: Nasdaq.com and their article: “AMAG Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 3 …” published on April 26, 2018 as well as Seekingalpha.com‘s news article titled: “AMAG Pharmaceuticals’ (AMAG) CEO William Heiden on Q1 2018 Results – Earnings Call Transcript” with publication date: May 03, 2018.

Bonterra Energy Corp., an upstream oil and gas company, engages in the production and sale of crude oil, natural gas, and natural gas liquids. The company has market cap of $539.30 million. It primarily focuses on the development of its Cardium land within the Pembina and Willesden Green areas located in central Alberta. It has a 215.87 P/E ratio. The firm also holds interests in the Shaunavon area in Saskatchewan, and the Prespatou area of northeast British Columbia.

Among 9 analysts covering Bonterra Energy Corp (TSE:BNE), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. Bonterra Energy Corp had 34 analyst reports since July 21, 2015 according to SRatingsIntel. As per Tuesday, June 28, the company rating was maintained by Desjardins Securities. The company was initiated on Wednesday, June 15 by IBC. Scotia Capital maintained Bonterra Energy Corp (TSE:BNE) on Wednesday, February 8 with “Sector Perform” rating. The rating was upgraded by Raymond James on Thursday, August 24 to “Strong Buy”. Scotia Capital maintained the shares of BNE in report on Wednesday, March 15 with “Sector Perform” rating. The firm has “Neutral” rating by Versant Partners given on Wednesday, December 21. The company was upgraded on Wednesday, December 21 by RBC Capital Markets. The firm has “Sector Perform” rating given on Friday, August 12 by Scotia Capital. The stock of Bonterra Energy Corp (TSE:BNE) has “Sector Perform” rating given on Friday, November 11 by Scotia Capital. As per Wednesday, March 15, the company rating was maintained by TD Securities.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *